A Phase I, Open-Label, Multi-Center, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 30 May 2012
At a glance
- Drugs Pasireotide (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Novartis
- 30 May 2012 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 29 May 2009 Actual patient number (34) added as reported by ClinicalTrials.gov.
- 29 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.